McNeil
This article was originally published in The Tan Sheet
Executive Summary
Sales increased 2.6% to $390 mil. in first quarter, J&J division reports April 17. "Positive results in...Children's Tylenol and Tylenol Cold as well as Children's Motrin and Motrin Cold were offset by declines in the adult analgesic category," VP-Investor Relations Helen Short says. J&J U.S. consumer health care sales rose 3.9% to $980 mil.; worldwide consumer health sales were $1.79 bil., rising 1.9%. Consolidated J&J sales of $7.79 bil. marked a 6.4% increase while U.S. sales spiked 9% to $4.58 bil. Net income jumped 14.2% to $1.5 bil. William McComb has risen to McNeil president after two years as VP-marketing. He succeeds Anthony Vernon, who moves to J&J's Centocor biotech subsidiary
You may also be interested in...
Whitehall Dimetapp Reformulations, New Products Drive U.S. Growth
Whitehall-Robins' quick reformulation and shipment of PPA-free Dimetapp products spurred a 50.3% increase in the brand's domestic sales during the first quarter. Dimetapp sales reached $23.6 mil. in the U.S., compared to $15.7 mil. in the year-ago period, Whitehall parent American Home Products said April 25.
Whitehall Dimetapp Reformulations, New Products Drive U.S. Growth
Whitehall-Robins' quick reformulation and shipment of PPA-free Dimetapp products spurred a 50.3% increase in the brand's domestic sales during the first quarter. Dimetapp sales reached $23.6 mil. in the U.S., compared to $15.7 mil. in the year-ago period, Whitehall parent American Home Products said April 25.
Whitehall Dimetapp Reformulations, New Products Drive U.S. Growth
Whitehall-Robins' quick reformulation and shipment of PPA-free Dimetapp products spurred a 50.3% increase in the brand's domestic sales during the first quarter. Dimetapp sales reached $23.6 mil. in the U.S., compared to $15.7 mil. in the year-ago period, Whitehall parent American Home Products said April 25.